RT Journal Article
SR Electronic
T1 Comparison of infected and vaccinated transplant recipients highlights the role of Tfh and neutralizing IgG in COVID-19 protection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.22.21260852
DO 10.1101/2021.07.22.21260852
A1 Charmetant, Xavier
A1 Espi, Maxime
A1 Benotmane, Ilies
A1 Heibel, Francoise
A1 Buron, Fanny
A1 Gautier-Vargas, Gabriela
A1 Delafosse, Marion
A1 Perrin, Peggy
A1 Koenig, Alice
A1 Cognard, Noelle
A1 Levi, Charlene
A1 Gallais, Floriane
A1 Manière, Louis
A1 Rossolillo, Paola
A1 Soulier, Eric
A1 Pierre, Florian
A1 Ovize, Anne
A1 Morelon, Emmanuel
A1 Defrance, Thierry
A1 Fafi-Kremer, Samira
A1 Caillard, Sophie
A1 Thaunat, Olivier
YR 2021
UL http://medrxiv.org/content/early/2021/07/24/2021.07.22.21260852.abstract
AB Transplant recipients, which receive therapeutic immunosuppression to prevent graft rejection, are characterized by high COVID-19-related mortality and defective response to vaccines. Having observed that previous infection by SARS-CoV-2 but not the standard “2 doses” scheme of vaccination, provided complete protection against COVID-19 to transplant recipients, we undertook this translational study to compare the cellular and humoral immune responses of these 2 groups of patients. Neutralizing anti-Receptor Binding Domain (RBD) IgG were identified as the critical immune effectors associated with protection. Generation of anti-RBD IgG was dependent upon spike-specific T follicular helper (Tfh) CD4+ T cells, which acted as limiting checkpoint. Tfh generation was impeded by high dose mycophenolate mofetil in non-responders to vaccine but not in infected patients, suggesting that increasing immunogenicity of vaccine could improve response rate to mRNA vaccine. This theory was validated in two independent prospective cohorts, in which administration of a 3rd dose of vaccine resulted in the generation of anti-RBD IgG in half of non-responders to 2 doses.One sentence summary The generation of neutralizing IgG, which protects kidney transplant recipients from COVID-19, requires T follicular helper cells.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04757883Funding StatementXC is supported by a funding from the Societe Francophone de Transplantation. ME is supported by the Hospices civils de Lyon and currently holds a poste accueil position funded by INSERM. OT is supported by the Etablissement Francais du Sang and the Fondation pour la Recherche Medicale (PME20180639518). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol complied with the tenets of the Helsinki Declaration and was approved by the Institutional Review Board (approval number: 18/21 03, Comite de Protection de Personnes Ouest IV Nantes) and registered on clinicaltrial.gov as NCT04757883.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesnot applicable